Stockreport

Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007

FIBROCELL SCIENCE INC COMMON  (FCSC) 
NASDAQ:AMEX Investor Relations: fibrocell.com
PDF   - Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-00 [Read more]